Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$273.40 USD

273.40
148,150

+1.69 (0.62%)

Updated Sep 18, 2025 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

by Zacks Equity Research

Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS

Shilpa Mete headshot

4 GARP Stocks to Scoop Up for Maximum Returns

by Shilpa Mete

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Zacks Equity Research

Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark

by Zacks Equity Research

Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.

Zacks Equity Research

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Zacks Equity Research

Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line

by Zacks Equity Research

Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.

Zacks Equity Research

QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio

by Zacks Equity Research

QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.

Zacks Equity Research

Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows

by Zacks Equity Research

Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

Zacks Equity Research

Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio

by Zacks Equity Research

Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.

Zacks Equity Research

Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical

by Zacks Equity Research

Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

by Trina Mukherjee

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Zacks Equity Research

Zacks.com featured highlights include: ResMed, Microsoft, Activision Blizzard, Best Buy and Insperity

by Zacks Equity Research

Zacks.com featured highlights include: ResMed, Microsoft, Activision Blizzard, Best Buy and Insperity

Zacks Equity Research

Is ResMed (RMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (RMD) Outperforming Other Medical Stocks This Year?

Sweta Killa headshot

5 Great Dividend Growth Stocks to Keep Volatility at Bay

by Sweta Killa

Dividend growth strategy is a major source of consistent income for investors in any type of market, though it doesn't offer dramatic price appreciation.

Zacks Equity Research

Canopy Growth (CGC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal second quarter.

Zacks Equity Research

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.

Zacks Equity Research

ResMed (RMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 29.59% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PAHC vs. RMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. RMD: Which Stock Is the Better Value Option?

Trina Mukherjee headshot

Medical Products' Oct 29 Earnings Roster: SYK, BAX & More

by Trina Mukherjee

Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

Zacks Equity Research

Why Earnings Season Could Be Great for ResMed (RMD)

by Zacks Equity Research

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.

Zacks Equity Research

Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat

by Zacks Equity Research

NextGen (NXGN) benefited from both its operating segments in Q2.

Zacks Equity Research

ResMed (RMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

by Zacks Equity Research

In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.